SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the target of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 900 shares, a decline of 25.0% from the February 13th total of 1,200 shares. Based on an average trading volume of 32,000 shares, the days-to-cover ratio is currently 0.0 days.

SAB Biotherapeutics Price Performance

NASDAQ SABSW opened at $0.03 on Tuesday. The company’s 50-day simple moving average is $0.06 and its 200 day simple moving average is $0.05. SAB Biotherapeutics has a twelve month low of $0.01 and a twelve month high of $0.18.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.